Renal and Systemic Effects of Calorie Restriction in Type-2 Diabetes Patients with Abdominal Obesity: a Randomized Controlled Trial

In type-2 diabetics with abdominal obesity, hyperfiltration is a risk factor for accelerated GFR decline and nephropathy. In this academic, single-center, parallel-group, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial ([ClinicalTRials.gov][1] number: [NCT01213212][2]), consenting >18-year-old, type-2 diabetics with waist circumference >94 (males) or >80 (females) cm, serum creatinine 120 ml/min) than non-hyperfiltering patients, and associated with body mass index, waist circumference, blood pressure, heart rate, HbA1C, blood glucose, LDL/HDL cholesterol ratio, C-reactive protein, Angiotensin-II, and albuminuria reduction and with increased glucose disposal rate (measured by hyperinsulinemic euglycemic clamps). Protein and sodium intake and concomitant treatments were similar between groups. CR was tolerated well. In Type-2 diabetics with abdominal obesity, CR ameliorates glomerular hyperfiltration, insulin sensitivity and other cardiovascular risk factors, effects that might translate into long-term nephro- and cardio-protection. [1]: http://ClinicalTRials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01213212&atom=%2Fdiabetes%2Fearly%2F2016%2F09%2F12%2Fdb16-0607.atom